| REPORT ATTRIBUTE |
DETAILS |
| Historical Period |
2019-2022 |
| Base Year |
2023 |
| Forecast Period |
2024-2032 |
| Cell Gene Therapy Biomanufacturing Market Size 2024 |
USD 13,847.5 million |
| Cell Gene Therapy Biomanufacturing Market, CAGR |
10.6% |
| Cell Gene Therapy Biomanufacturing Market Size 2032 |
USD 31,003.62 million |
Market Overview:
The Cell Gene Therapy Biomanufacturing market is poised for substantial growth, with its market size projected to reach USD 13,847.5 million in 2024, and expanding to USD 31,003.62 million by 2032. This significant growth reflects a robust CAGR of 10.6% over the forecast period.
The increasing adoption of cell and gene therapies, driven by their potential to treat various chronic and genetic disorders, is a key factor contributing to the market’s expansion. Advances in biomanufacturing technologies and the growing number of approved cell and gene therapy products further accelerate the market’s growth trajectory.
Several market drivers are fuelling this growth. The rise in the prevalence of chronic and genetic diseases, combined with an aging population, has heightened the demand for innovative therapies, including cell and gene therapies. Furthermore, advancements in biomanufacturing processes, such as automation and the use of artificial intelligence (AI), are improving the efficiency and scalability of production, making these therapies more accessible. Additionally, increasing investments in research and development by both public and private sectors, coupled with favourable regulatory frameworks, are supporting the rapid commercialization of new cell and gene therapy products.
Geographically, North America dominates the Cell Gene Therapy Biomanufacturing market, attributed to the presence of major biopharmaceutical companies, a well-established healthcare infrastructure, and significant investment in R&D activities. Europe follows closely, driven by increasing government initiatives and funding in cell and gene therapy research. The Asia-Pacific region is anticipated to witness the highest growth rate during the forecast period, due to the expanding healthcare infrastructure, rising awareness of advanced therapies, and increasing investments from global players. The growing patient pool in emerging economies such as China and India further bolster the market’s growth in this region.
Access crucial information at unmatched prices!
Request your free sample report today & start making informed decisions powered by Credence Research!
Download Free Sample
Market Drivers:
Increasing Prevalence of Chronic and Genetic Diseases:
The rising incidence of chronic and genetic disorders is a primary driver of the Cell Gene Therapy Biomanufacturing market. According to the World Health Organization (WHO), non-communicable diseases (NCDs) account for approximately 71% of all global deaths each year, underscoring the urgent need for innovative therapeutic solutions. Cell and gene therapies offer the potential to address the underlying causes of many of these conditions, leading to increased demand for biomanufacturing capabilities. This demand is further driven by the growing number of patients diagnosed with rare genetic disorders, which according to the National Institutes of Health (NIH), affect about 30 million Americans.
Technological Advancements in Biomanufacturing:
Advances in biomanufacturing technologies are significantly enhancing the scalability and efficiency of cell and gene therapy production. Automation, artificial intelligence (AI), and machine learning are being increasingly integrated into manufacturing processes, leading to improved precision and reduced costs. For instance, companies like Lonza Group and Thermo Fisher Scientific have developed automated platforms for cell therapy production, which streamline workflows and enhance consistency. Additionally, the adoption of single-use technologies in biomanufacturing is reducing the risk of contamination and accelerating the overall production process, further driving market growth.
Rising Investments in Research and Development:
The Cell Gene Therapy Biomanufacturing market is benefiting from substantial investments in research and development by both public and private sectors. Governments across the globe are recognizing the potential of these therapies and are providing significant funding to support their development. For example, the U.S. government has invested billions of dollars in initiatives like the Cancer Moonshot and the 21st Century Cures Act, which aim to accelerate the development and approval of cell and gene therapies. Similarly, biopharmaceutical companies are increasing their R&D budgets to explore new applications and improve existing manufacturing processes.
Supportive Regulatory Frameworks and Approvals:
Favourable regulatory environments are playing a crucial role in the growth of the Cell Gene Therapy Biomanufacturing market. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are streamlining approval processes for cell and gene therapies, recognizing their potential to address unmet medical needs. The FDA, for instance, has granted several regenerative medicine advanced therapy (RMAT) designations, which expedite the development and review of promising therapies. This regulatory support is encouraging companies to invest more in biomanufacturing capabilities, driving the market forward.
Market Trends:
Adoption of Advanced Manufacturing Technologies:
The Cell Gene Therapy Biomanufacturing market is witnessing a significant shift towards the adoption of advanced manufacturing technologies. Companies are increasingly leveraging automation, artificial intelligence (AI), and digital twins to optimize production processes. For instance, GE Healthcare has introduced digital twin technology, which allows manufacturers to create a virtual model of the production process, enabling real-time monitoring and optimization. This trend not only improves efficiency and scalability but also reduces production costs, making advanced therapies more accessible.
Expansion of Contract Development and Manufacturing Organizations (CDMOs):
The rise of Contract Development and Manufacturing Organizations (CDMOs) is a notable trend in the Cell Gene Therapy Biomanufacturing market. As biopharmaceutical companies focus on innovation and reducing time-to-market, they are increasingly outsourcing their manufacturing needs to specialized CDMOs. For example, companies like WuXi AppTec and Catalent have expanded their biomanufacturing capacities to meet the growing demand for cell and gene therapy production. This trend allows smaller biotech firms to access state-of-the-art manufacturing facilities without the need for substantial capital investment, thereby accelerating the commercialization of new therapies.
Increased Focus on Personalized Medicine:
The growing emphasis on personalized medicine is driving advancements in the Cell Gene Therapy Biomanufacturing market. Personalized therapies, which are tailored to individual patients based on their genetic makeup, are gaining traction as they offer improved efficacy and reduced side effects. The U.S. Food and Drug Administration (FDA) has reported a steady increase in the approval of personalized therapies over the past decade. For instance, Novartis has developed CAR-T cell therapies, such as Kymriah, which are customized to each patient’s unique genetic profile, marking a significant trend towards individualized treatment approaches.
Collaboration and Partnerships Across the Industry:
Collaboration and partnerships among pharmaceutical companies, research institutions, and technology providers are becoming increasingly common in the Cell Gene Therapy Biomanufacturing market. These collaborations are aimed at combining expertise and resources to accelerate innovation and address the complex challenges of cell and gene therapy production. For example, Pfizer has partnered with biotech firms like Spark Therapeutics to develop and commercialize gene therapies for rare diseases. Such partnerships are not only driving technological advancements but also facilitating knowledge sharing and the development of standardized manufacturing processes across the industry.
Market Challenges Analysis:
High Costs and Complex Manufacturing Processes:
The production of cell and gene therapies requires specialized equipment and infrastructure, which are inherently expensive. The complexity of the manufacturing process, including the need for precise conditions and quality control, further escalates costs.
Regulatory Hurdles:
Navigating the regulatory landscape for cell and gene therapies is challenging. The approval process is rigorous, requiring extensive clinical trials and documentation. Delays in regulatory approvals can hinder the timely introduction of new therapies to the market.
Supply Chain Disruptions:
The COVID-19 pandemic highlighted vulnerabilities in the supply chain for biomanufacturing materials. Shortages of critical supplies and disruptions in logistics have significantly impacted production timelines and costs.
Scalability Issues:
Scaling up production from research to commercial levels presents significant challenges. Many biomanufacturing processes are not yet optimized for large-scale production, leading to bottlenecks and inefficiencies.
Labor Shortages:
The industry faces a shortage of skilled labor, which is essential for the highly specialized tasks involved in cell and gene therapy production. This shortage can lead to delays and increased costs.
Market Access and Reimbursement:
Securing market access and reimbursement for cell and gene therapies is complex. Payers often require extensive evidence of clinical and economic benefits, which can be challenging to provide given the novel nature of these therapies.
Safety and Efficacy Concerns:
Ensuring the safety and efficacy of cell and gene therapies is paramount. Adverse events or lack of efficacy in clinical trials can lead to setbacks and increased scrutiny from regulators and the public.
Market Segmentation Analysis:
By Type:
The market is categorized into consumables, equipment, and software solutions. Consumables include reagents, media, and other materials essential for biomanufacturing processes. Equipment encompasses bioreactors, centrifuges, and other machinery required for production. Software solutions involve digital tools for process optimization and quality control.
By Technology:
The market is segmented based on the technologies employed in biomanufacturing. Key technologies include upstream processing, downstream processing, and single-use systems. Upstream processing involves cell culture and fermentation, while downstream processing includes purification and formulation. Single-use systems are gaining traction due to their cost-effectiveness and reduced risk of contamination.
By End User:
The end-user segment comprises life science companies, contract research organizations (CROs), contract manufacturing organizations (CMOs), and cell banks. Life science companies are the primary users, leveraging biomanufacturing for developing and commercializing therapies. CROs and CMOs provide specialized services, including research and large-scale production. Cell banks store and supply cell lines for research and therapeutic purposes.
Segmentation:
By Product Type
- Consumables
- Equipment
- Software Solutions
By Usage
- Commercial Stage Manufacturing
- Research Stage Manufacturing
By Application
- Upstream Processing
- Harvesting
- Downstream Processing
By End User
- Life Science Companies
- Contract Research Organizations (CROs)
- Contract Manufacturing Organizations (CMOs)
- Cell Bank
By Region
- North America
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Regional Analysis:
North America
North America holds the largest share of the Cell Gene Therapy Biomanufacturing market, accounting for approximately 40% of the global market in 2024. This dominance is largely attributed to the presence of major biopharmaceutical companies, advanced healthcare infrastructure, and significant investment in research and development (R&D). The United States, in particular, is a key contributor, supported by favorable regulatory frameworks such as the U.S. Food and Drug Administration’s (FDA) Regenerative Medicine Advanced Therapy (RMAT) designation, which accelerates the approval process for innovative therapies. Additionally, the region benefits from substantial government and private sector funding, further driving market growth.
Europe
Europe follows closely, with a market share of around 30%. The region’s growth is driven by strong governmental support and funding for cell and gene therapy research. Countries like Germany, the United Kingdom, and France are leading the market due to their robust healthcare systems, well-established biomanufacturing facilities, and a high concentration of academic and research institutions. The European Medicines Agency (EMA) plays a crucial role in streamlining regulatory approvals, which enhances the region’s attractiveness for biopharmaceutical companies. Furthermore, increasing collaborations between academia and industry are contributing to advancements in cell gene therapy manufacturing processes across Europe.
Asia-Pacific
The Asia-Pacific region is expected to witness the highest growth rate during the forecast period, holding a market share of approximately 20%. This growth is driven by the expanding healthcare infrastructure, rising awareness of advanced therapies, and increasing investments from global players. China and Japan are leading markets in this region, with significant investments in biomanufacturing capabilities and favorable government policies that encourage innovation. Additionally, the growing patient pool in emerging economies such as India and South Korea, along with the increasing prevalence of chronic and genetic diseases, is further propelling market growth in the region.
Latin America and Middle East & Africa
Latin America and the Middle East & Africa collectively account for the remaining 10% of the global market. These regions are gradually emerging as potential markets due to improving healthcare infrastructures and increasing governmental efforts to enhance access to advanced therapies. However, challenges such as limited funding, lack of skilled professionals, and underdeveloped regulatory frameworks still pose significant barriers to market growth. Despite these challenges, countries like Brazil and South Africa are making strides in adopting cell and gene therapies, supported by collaborations with international biopharmaceutical companies aiming to expand their footprint in these regions.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
Key Player Analysis:
- Lonza Group
- Thermo Fisher Scientific
- WuXi AppTec
- Catalent, Inc.
- Novartis AG
- Fujifilm Diosynth Biotechnologies
- Bluebird Bio
- Sangamo Therapeutics
- Pfizer Inc.
- Oxford Biomedica
Competitive Analysis:
The Cell Gene Therapy Biomanufacturing market is highly competitive, driven by the presence of established biopharmaceutical companies and specialized Contract Development and Manufacturing Organizations (CDMOs). Key players like Lonza Group, Thermo Fisher Scientific, and WuXi AppTec dominate the market, offering comprehensive end-to-end solutions that range from early-stage development to commercial-scale manufacturing. These companies leverage advanced technologies, such as automation and AI, to enhance production efficiency and scalability. Additionally, strategic collaborations and partnerships are common, as seen with Novartis and Oxford Biomedica, where companies combine expertise to accelerate innovation and expand market reach. The competitive landscape is further intensified by the entry of new players and the continuous advancements in biomanufacturing processes. As the demand for cell and gene therapies grows, competition is expected to intensify, driving further innovation and expansion in the market.
Recent Developments:
- CRISPR-Based Gene Therapy Approval (2024): The U.S. FDA approved the first CRISPR-based gene editing therapy, Casgevy, in 2024. Developed by Vertex Pharmaceuticals and CRISPR Therapeutics, this therapy marks a significant milestone in gene editing, specifically targeting sickle cell disease and transfusion-dependent beta-thalassemia. This approval is expected to pave the way for more advanced gene-editing therapies in the future.
- Expansion of Allogeneic T-Cell Therapies (2024): The FDA is anticipated to grant its first approval for an allogeneic T-cell therapy in 2024, marking a major advancement in the field. Allogeneic therapies, which use donor cells rather than the patient’s own, have the potential to lower costs and improve accessibility, making these treatments more scalable and widely available.
- Adoption of Digital Twin Technology (2023): GE Healthcare introduced digital twin technology in 2023, revolutionizing the biomanufacturing process for cell and gene therapies. This technology allows for the creation of virtual models of production processes, enabling real-time monitoring and optimization, which is expected to significantly improve manufacturing efficiency and reduce costs.
- Increased Regulatory Approvals for Gene Therapies (2023): In 2023, the U.S. FDA approved five gene therapies for rare genetic diseases, signaling a growing acceptance and trust in these advanced treatments. The year also saw approvals in Europe and the expectation for further expansion in 2024, reflecting the industry’s momentum and the increasing adoption of these therapies.
Market Concentration & Characteristics:
The Cell Gene Therapy Biomanufacturing market is moderately concentrated, with a few key players holding significant market shares. Companies like Lonza Group, Thermo Fisher Scientific, and WuXi AppTec dominate the market due to their extensive biomanufacturing capabilities, advanced technologies, and comprehensive service offerings. The market is characterized by high barriers to entry, primarily due to the complex and capital-intensive nature of cell and gene therapy production. The need for specialized knowledge, advanced technology, and stringent regulatory compliance further limits the number of competitors. Additionally, the market is witnessing increasing consolidation, with major players engaging in strategic acquisitions and collaborations to expand their capabilities and market presence. Despite these barriers, the market continues to attract new entrants, particularly smaller biotech firms and Contract Development and Manufacturing Organizations (CDMOs), aiming to carve out niches within this rapidly growing industry.
Report Coverage:
The research report offers an in-depth analysis based on Product Type, Usage, Application, and End User. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook:
- Increased adoption of automation and digital solutions will streamline manufacturing processes, improving efficiency and reducing costs.
- Advanced gene editing technologies like CRISPR will drive innovation in developing more precise and effective therapies.
- Expansion of allogeneic “off-the-shelf” cell therapies will broaden treatment accessibility and reduce manufacturing complexities.
- Growing focus on developing therapies for solid tumors will open new market opportunities beyond hematological cancers.
- Integration of artificial intelligence in clinical trial design and regulatory processes will accelerate therapy development and approval.
- Emergence of highly personalized treatment plans tailored to individual patient genetics will enhance therapeutic outcomes.
- Continued investment in specialized manufacturing facilities and equipment will support the growing demand for cell and gene therapies.
- Advancements in delivery mechanisms, such as targeted nanoparticles and viral vectors, will improve treatment efficacy and expand treatable conditions.
- Increased collaboration between industry players, academic institutions, and regulatory bodies will foster innovation and streamline approval processes.
- Focus on optimizing upstream and downstream processing will enhance production yields and quality, potentially reducing therapy costs.
